ZM 447439

Catalog No.S1103

For research use only.

ZM 447439 is a selective and ATP-competitive inhibitor for Aurora A and Aurora B with IC50 of 110 nM and 130 nM, respectively. It is more than 8-fold selective for Aurora A/B than MEK1, Src, Lck and has little effect against CDK1/2/4, Plk1, Chk1, etc.

ZM 447439 Chemical Structure

CAS No. 331771-20-1

Selleck's ZM 447439 has been cited by 52 publications

Purity & Quality Control

Choose Selective Aurora Kinase Inhibitors

Other Aurora Kinase Products

Biological Activity

Description ZM 447439 is a selective and ATP-competitive inhibitor for Aurora A and Aurora B with IC50 of 110 nM and 130 nM, respectively. It is more than 8-fold selective for Aurora A/B than MEK1, Src, Lck and has little effect against CDK1/2/4, Plk1, Chk1, etc.
Features An Aurora selective ATP-competitive inhibitor.
Targets
Aurora A [1]
(Cell-free assay)
Aurora B [1]
(Cell-free assay)
LCK [1]
(Cell-free assay)
Src [1]
(Cell-free assay)
MEK1 [1]
(Cell-free assay)
110 nM 130 nM 880 nM 1.03 μM 1.79 μM
In vitro

In vitro, ZM-447439 selectively inhibits recombinant human Aurora A and B with IC50 values of 110 and 130 nM, respectively, while other protein kinases of diverse structural types including the mitotic kinases CDK1 and PLK1 are inhibited with IC50 values >10 μM. [1] Aurora kinase inhibitor, ZM-447439 time- and dose-dependently inhibits the growth of all three cell lines with IC50 values of 3 μM (BON), 0.9 μM (QGP-1) and 3 μM (MIP-101) after 72 hours of continuous exposure. In addition, ZM-447439 potently induces cell apoptosis by promoting DNA fragmentation and caspase 3 and 7 activation, and arrests GEP-NET cells in the G0 /G1and G2/M phase of the cell cycle. [2] In mouse embryo, inhibition of Aurora kinase activity by ZM-447439 results in abnormalities during mitosis by regulating the phosphorylation of histone H3 serine 10 (H3S10Ph) from G2 to metaphase with different perturbations in each embryonic cycle. [3] A recent study shows that ZM-447439 exhibits growth inhibitory and proapoptotic effect on cervical cancer SiHa cells, and enhances the chemosensitivity to cisplatin. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human EoL-1-cell MlvHS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MXLJcohq[mm2aX;uJI9nKGi3bXHuJGVwVC1zLXPlcIwh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjF6Nke4JO69VQ>? NHvze4hUSU6JRWK=
MCF7 cell M2Ph[3Bzd2yrZnXyZZRqd25iYYPzZZk> NYPHT2NVSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBOS0Z5IHPlcIwhdGmwZTygTWM2OD1yLkG5PEDPxE1? MWWxOlM{PzF{Mh?=
human P12-ICHIKAWA cell M{GzPWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NYK5N4JnUW6qaXLpeIlwdiCxZjDoeY1idiCSMUKtTWNJUUuDV1GgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlIzPDRzIN88US=> NVLjSlJJW0GQR1XS
human KARPAS-45 cell MXHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NF3GdJVKdmirYnn0bY9vKG:oIHj1cYFvKEuDUmDBV{01PSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwM{ixNlgh|ryP MoXsV2FPT0WU
human ES3 cell MmDIS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M4rF[mlvcGmkaYTpc44hd2ZiaIXtZY4hTVN|IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD60O|MzKM7:TR?= MmLYV2FPT0WU
human ES8 cell MYrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NV3Uc4ltUW6qaXLpeIlwdiCxZjDoeY1idiCHU{igZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlQ6QDB4IN88US=> MVnTRW5ITVJ?
human TE-11 cell NFzlSGpIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M2m0WmlvcGmkaYTpc44hd2ZiaIXtZY4hXEVvMUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlU{PzB|IN88US=> NX;IS21mW0GQR1XS
human RS4-11 cell M2rrNGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MUTJcohq[mm2aX;uJI9nKGi3bXHuJHJUPC1zMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuOVU1PCEQvF2= NHftWYhUSU6JRWK=
human MOLT-16 cell MUnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MnG1TY5pcWKrdHnvckBw\iCqdX3hckBOV0yWLUG2JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE43ODl4MTFOwG0> MVTTRW5ITVJ?
human RKO cell M4PtcWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NXPKVms4UW6qaXLpeIlwdiCxZjDoeY1idiCUS1:gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlcxPjV4IN88US=> M2TNPHNCVkeHUh?=
human MV-4-11 cell NH3lV2hIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NXvl[GR[UW6qaXLpeIlwdiCxZjDoeY1idiCPVj20MVEyKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC55OU[zJO69VQ>? NVf2e3FSW0GQR1XS
human SW954 cell NULTRVdYT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M1vNN2lvcGmkaYTpc44hd2ZiaIXtZY4hW1d7NUSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlg{PjN3IN88US=> MVPTRW5ITVJ?
human BE-13 cell MXHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MmPnTY5pcWKrdHnvckBw\iCqdX3hckBDTS1zMzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuPFQ1OThizszN NEXoNHZUSU6JRWK=
human MOLT-4 cell Mn;zS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M{WwWWlvcGmkaYTpc44hd2ZiaIXtZY4hVU:OVD20JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE45QTl5ODFOwG0> NFvuO|ZUSU6JRWK=
human NBsusSR cell MWfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NV3ScGdIUW6qaXLpeIlwdiCxZjDoeY1idiCQQoP1d3NTKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC57MUO4O{DPxE1? NWDoUYtkW0GQR1XS
human H9 cell MmjsS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M{\ldGlvcGmkaYTpc44hd2ZiaIXtZY4hUDliY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkmyPVc6KM7:TR?= NFPlfJhUSU6JRWK=
human A172 cell MnHlS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M1vhN2lvcGmkaYTpc44hd2ZiaIXtZY4hSTF5MjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuPVg1OTFizszN NF7JOnJUSU6JRWK=
human ES5 cell MVvHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MkHMTY5pcWKrdHnvckBw\iCqdX3hckBGWzViY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zLkCwNlQ5KM7:TR?= NYPQS4J6W0GQR1XS
human SBC-1 cell NEDIcGRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M3\rbmlvcGmkaYTpc44hd2ZiaIXtZY4hW0KFLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlA{QTJ6IN88US=> M1T4e3NCVkeHUh?=
human NCI-H209 cell NIDqXmZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NEXVXWFKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INlA6KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OS5zNk[wNkDPxE1? MVfTRW5ITVJ?
human NKM-1 cell MXjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MWLJcohq[mm2aX;uJI9nKGi3bXHuJG5MVS1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MT6xOlc6QCEQvF2= MoXBV2FPT0WU
human NCI-H720 cell MXjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NFj6S5JKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3IO|IxKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OS5{ME[yO{DPxE1? M4K1NnNCVkeHUh?=
human KE-37 cell MoH4S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M4HYXmlvcGmkaYTpc44hd2ZiaIXtZY4hU0VvM{egZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlIyOzh6IN88US=> MX\TRW5ITVJ?
human SW48 cell NGLTXZpIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NUjLNJFGUW6qaXLpeIlwdiCxZjDoeY1idiCVV{S4JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU4zOzF3NTFOwG0> NUTPNItCW0GQR1XS
human IST-SL1 cell NX7ET|NtT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NUO5eJNjUW6qaXLpeIlwdiCxZjDoeY1idiCLU2StV2wyKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OS5|MUeyO{DPxE1? NHLYb2pUSU6JRWK=
human SK-NEP-1 cell MnfTS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? Mlm2TY5pcWKrdHnvckBw\iCqdX3hckBUUy2QRWCtNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvOzZ2OUig{txO MkHzV2FPT0WU
human NOMO-1 cell M1raN2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MXzJcohq[mm2aX;uJI9nKGi3bXHuJG5QVU9vMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuN|Y4OjVizszN NYLTe4p{W0GQR1XS
human DOHH-2 cell MkHqS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M4PpTmlvcGmkaYTpc44hd2ZiaIXtZY4hTE:KSD2yJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU41ODJ5NjFOwG0> M3nLc3NCVkeHUh?=
human ABC-1 cell MYjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M1S5SGlvcGmkaYTpc44hd2ZiaIXtZY4hSUKFLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlQxOzV{IN88US=> M2\VbXNCVkeHUh?=
human Ramos-2G6-4C10 cell MV\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? Mor2TY5pcWKrdHnvckBw\iCqdX3hckBT[W2xcz2yS|YuPENzMDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuOFA3ODVizszN MY\TRW5ITVJ?
human EM-2 cell M3vzUmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M3rXemlvcGmkaYTpc44hd2ZiaIXtZY4hTU1vMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuOFE4OjFizszN MlvpV2FPT0WU
human NB14 cell M3jYS2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MWnJcohq[mm2aX;uJI9nKGi3bXHuJG5DOTRiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zLkW1OlIyKM7:TR?= MVfTRW5ITVJ?
human MOLT-13 cell M1ThcWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M2jMPGlvcGmkaYTpc44hd2ZiaIXtZY4hVU:OVD2xN{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvPTZ5ME[g{txO NFL3ZpFUSU6JRWK=
human ECC10 cell NWn2R45WT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NGntWYlKdmirYnn0bY9vKG:oIHj1cYFvKEWFQ{GwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU43OzN3MzFOwG0> MnrvV2FPT0WU
human LK-2 cell NUHjSnNiT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MYTJcohq[mm2aX;uJI9nKGi3bXHuJGxMNTJiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zLk[0OVk1KM7:TR?= Mo\CV2FPT0WU
human CTB-1 cell NEWxR|dIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M4riSGlvcGmkaYTpc44hd2ZiaIXtZY4hS1SELUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlY4ODh{IN88US=> NETTVpRUSU6JRWK=
human NCI-H1581 cell MnHnS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MXrJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMUW4NUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvPjd3NTFOwG0> M4DaV3NCVkeHUh?=
human COLO-800 cell NHHoWY9Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= NYjOTG52UW6qaXLpeIlwdiCxZjDoeY1idiCFT1zPMVgxOCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTFwN{CzPFIh|ryP MV;TRW5ITVJ?
human NB7 cell NVziSVhNT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NYPUWnNtUW6qaXLpeIlwdiCxZjDoeY1idiCQQkegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlc2Ojl5IN88US=> M1jnSXNCVkeHUh?=
human LAMA-84 cell NUTuN3BIT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MWrJcohq[mm2aX;uJI9nKGi3bXHuJGxCVUFvOESgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlc2PTJizszN MWjTRW5ITVJ?
human HCT-116 cells NFn6e29Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= M{DDfmlvcGmkaYTpc44hd2ZiaIXtZY4hUEOWLUGxOkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvQDB7MEig{txO MkXMV2FPT0WU
SK-UT-1 cell MoTyS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? Mny3TY5pcWKrdHnvckBw\iCqdX3hckBUUy2XVD2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU45OTV|IN88US=> M4LUe3NCVkeHUh?=
human H4 cell MUfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NFTIPFRKdmirYnn0bY9vKG:oIHj1cYFvKEh2IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MT64NVU4QCEQvF2= MXXTRW5ITVJ?
human CAL-51 cell NXGzdWYxT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MoDITY5pcWKrdHnvckBw\iCqdX3hckBESUxvNUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlg{QDR3IN88US=> MW\TRW5ITVJ?
human LoVo cells MXPQdo9tcW[ncnH0bY9vKGG|c3H5 MVG3NkBp NGDleHZCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFzvWo8h[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IF3UWE1j[XOnZDDXV3Q5KHKnYXflcpQh[XO|YYmsJGlEPTB;MT65JO69VQ>? MVOyOVI4ODRyMx?=
human HN cell NFXaZm9Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= NIf3eIRKdmirYnn0bY9vKG:oIHj1cYFvKEiQIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MT65NlUyKM7:TR?= NFXEe2lUSU6JRWK=
human L-363 cell NV7zdphoT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MUDJcohq[mm2aX;uJI9nKGi3bXHuJGwuOzZ|IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MT65OVEzKM7:TR?= NIS1UHpUSU6JRWK=
human NCI-H747 cell M1PRRmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NE\BOIRKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3IO|Q4KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oi5yM{O1N{DPxE1? Ml3BV2FPT0WU
human A498 cell NEnpbZZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MXnJcohq[mm2aX;uJI9nKGi3bXHuJGE1QThiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{LkO2Olkh|ryP MnTwV2FPT0WU
Assay
Methods Test Index PMID
Western blot p53 / p21 / p-p38 / p38 ; pHistone H3 / CEM ; BubR1 / MAD2 / Cyclin B1 23759594 22359551 26188358
Immunofluorescence p21 ; p53 ; Aurora B / Survivin 23759594 12719470

Protocol (from reference)

Kinase Assay:[1]
  • In vitro kinase assays :

    Recombinant Aurora A and B are expressed as NH2-terminal His6-tagged fusion proteins using a baculovirus expression system. Aurora A is purified by affinity chromatography using Ni-NTA agarose, and Aurora B is purified by ion exchange chromatography using CM Sepharose Fast Flow. 1 ng purified recombinant enzyme is added to a reaction cocktail containing 25 mM Tris-HCl, pH 7.5, 12.5 mM KCl, 2.5 mM NaF, 0.6 mM DTT, 6.25 mM MnCl2, 10 μM peptide substrate, 10 μM for Aurora A or 5 μM ATP for Aurora B, and 0.2 μCi γ-[33P]ATP (specific activity ≥2,500 Ci/mmol), and is then incubated at RT for 60 minutes. Reactions are stopped by addition of 20% phosphoric acid, and the products are captured on P30 nitrocellulose filters and assayed for incorporation of 33P with a BetaplateTM counter. No enzyme and no compound control values are used to determine the concentration of ZM447439, which gave 50% inhibition of enzyme activity. Further details are available on request from Nicholas Keen.

Cell Research:[2]
  • Cell lines: BON, QGP-1 and MIP-101 cells
  • Concentrations: 0-5 μM
  • Incubation Time: 72 hours
  • Method: Cell number is evaluated by crystal violet staining. In brief, cells in 96-well plates are fixed with 1% glutaraldehyde. Then cells are stained with 0.1% crystal violet. The unbound dye is removed by washing with water. Bound crystal violet is solubilized with 0.2% Triton X-100. Light extinction which increases linearly with the cell number is analyzed at 570 nm using an ELISA reader.

Solubility (25°C)

In vitro

DMSO 103 mg/mL
(200.54 mM)
Water Insoluble
Ethanol Insoluble

In vivo

Add solvents to the product individually and in order
(Data is from Selleck tests instead of citations):
30% PEG400+0.5% Tween80+5% propylene glycol
For best results, use promptly after mixing.

30 mg/mL

Chemical Information

Molecular Weight 513.59
Formula

C29H31N5O4

CAS No. 331771-20-1
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles COC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=C(C=C3)NC(=O)C4=CC=CC=C4)OCCCN5CCOCC5

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy ZM 447439 | ZM 447439 supplier | purchase ZM 447439 | ZM 447439 cost | ZM 447439 manufacturer | order ZM 447439 | ZM 447439 distributor